Literature DB >> 9599198

The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn disease.

W Strober, B R Lúdvíksson, I J Fuss.   

Abstract

In recent years, it has become apparent that overproduction of the Th1 cytokines interleukin-12 and interferon-gamma is the probable driving force behind murine models of intestinal inflammation resembling Crohn disease and intestinal inflammation in humans with Crohn disease. In addition, studies of murine models strongly suggest that this overproduction is associated with inadequate secretion of the counter-regulatory and anti-inflammatory cytokine transforming growth factor-beta. Thus, mucosal inflammation in models (and possibly in humans) may result from an imbalance between normally occurring positive (immunogenic or inflammatory) responses and negative (tolerogenic or anti-inflammatory) mucosal immune responses. These new findings and the hypotheses that arise from them are being used to construct new approaches to the treatment of Crohn disease that are based on the administration of anti-inflammatory cytokines and anti-cytokine antibodies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9599198     DOI: 10.7326/0003-4819-128-10-199805150-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  32 in total

1.  Transforming growth factor beta1 is expressed in the jejunum after experimental Cryptosporidium parvum infection in humans.

Authors:  P Robinson; P C Okhuysen; C L Chappell; D E Lewis; I Shahab; S Lahoti; A C White
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

Review 2.  Clinical aspects and pathophysiology of inflammatory bowel disease.

Authors:  Barbara A Hendrickson; Ranjana Gokhale; Judy H Cho
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

3.  Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease.

Authors:  S Dionne; S Laberge; C Deslandres; E G Seidman
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

Review 4.  Evaluation of new therapies for inflammatory bowel disease.

Authors:  E Carty; D S Rampton
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 5.  Mucosal T lymphocytes--peacekeepers and warriors.

Authors:  Hilde Cheroutre; Mitchell Kronenberg
Journal:  Springer Semin Immunopathol       Date:  2005-06-02

6.  Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice.

Authors:  Norihiko Watanabe; Koichi Ikuta; Kazuichi Okazaki; Hiroshi Nakase; Yasuhiko Tabata; Minoru Matsuura; Hiroyuki Tamaki; Chiharu Kawanami; Tasuku Honjo; Tsutomu Chiba
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

7.  Concurrent infection with Schistosoma mansoni attenuates inflammation induced changes in colonic morphology, cytokine levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats.

Authors:  T G Moreels; R J Nieuwendijk; J G De Man; B Y De Winter; A G Herman; E A Van Marck; P A Pelckmans
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

8.  Impaired rejection and mucosal injury of small intestinal allografts lacking the interferon-gamma receptor.

Authors:  Andrew M Veitch; Lisa M Higgins; Mona Bajaj-Elliot; Michael J G Farthing; Thomas T MacDonald
Journal:  Int J Exp Pathol       Date:  2003-06       Impact factor: 1.925

9.  Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease.

Authors:  S Schreiber; P Rosenstiel; J Hampe; S Nikolaus; B Groessner; A Schottelius; T Kühbacher; J Hämling; U R Fölsch; D Seegert
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

10.  Dendritic cells stimulated with Actinobacillus actinomycetemcomitans elicit rapid gamma interferon responses by natural killer cells.

Authors:  T Kikuchi; C L Hahn; S Tanaka; S E Barbour; H A Schenkein; J G Tew
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.